Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Innovative Skincare Clinical presents study results and product evaluations to help you assess effectiveness and safety in modern skincare.
1,173 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A major fund’s exit from Ocular Therapeutix raises questions about timing, liquidity, and sector signals. This articl...
Small-cap biotech Aethlon Medical faces a pivotal year in 2026. This guide breaks down what to watch in aethlon (aemd...
Momentum can carry stocks far, but savvy investors still want a plan. This article profiles three soaring stocks that...
Iovance surged this week after robust Q4 results and a Philadelphia manufacturing moat highlighted by a 32 day turnar...
When a company's CFO divests shares amid a strong stock run, investors want to know what it means. This deep dive exp...
Jaguar (JAGX) 2025 earnings show a company shifting from product-driven revenue to licensing cash. This piece breaks ...
Pfizer is stepping into a high-stakes arena long led by Lilly and Novo Nordisk. This article analyzes what pfizer's w...
Vertex Pharmaceuticals just made aBold move that could reshape its growth trajectory. This guide breaks down the deal...
Aave’s UK units Push Labs Ltd. and Push Virtual Assets Ltd. have won FCA registration to run crypto asset exchange se...
Looking for value and growth in one parcel? This guide dives into the best growth etfs under $20, how to evaluate the...
Defense technology is approaching a market shakeout as government procurement reforms accelerate purchases and ventur...